Galectin 3C

Drug Profile

Galectin 3C

Alternative Names: Gal-3C; Galectin-3C

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator MandalMed
  • Developer MandalMed; Texas Tech University Health Sciences Center; University of California at San Francisco
  • Class Antifibrotics; Galectins
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Cancer; Lymphoma

Highest Development Phases

  • Preclinical Breast cancer
  • Research Fibrosis; Lymphoma
  • No development reported Multiple myeloma

Most Recent Events

  • 02 Aug 2016 Preclinical development is ongoing for Breast cancer in the US
  • 02 Aug 2016 Galectin 3C is available for licensing as of 02 Aug 2016. http://www.mandalmed.com/
  • 02 Aug 2016 Early research in Lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top